OpenAI's Former Science Chief Just Raised $215M to Build Robot-Run Drug Labs

OpenAI's former science chief is betting $215 million that the next great AI breakthrough won't happen in a chat window — it'll happen in a chemistry lab.

Kevin Weil, who led OpenAI's science initiatives until earlier this year, has launched Warp Sciences, a startup building automated chemistry labs where robots make and test the molecules behind new medicines. The $215 million Series A round, led by Lightspeed at a reported $865 million valuation, was announced October 22, 2026.

Robots learn chemistry from humans — literally

Here's the part that grabbed me: human chemists will wear cameras and sensor-lined gloves while doing their work, so the robots can watch and learn real lab technique. Over time, the labs are supposed to run around the clock, with every experiment feeding data back into Warp's AI models — each cycle making the next one smarter.

Warp isn't trying to discover drugs itself. Its first service is narrower: lead-optimization synthesis, the grind of making hundreds or thousands of variations of a promising molecule so scientists can compare and pick winners. That physical work is the slowest part of drug discovery — and it's where AI is now going to get its hands dirty, literally.

Why bring the lab back to America

For years, this labor-intensive chemistry has been outsourced to contractors in China, like WuXi AppTec. Warp wants to reshore it to the U.S., matching that overseas caliber from automated labs at home — no markup, no geopolitical supply-chain anxiety, and no worrying about who sees your sensitive molecular data. AI is increasingly helping design new drugs — see our recent piece on Hugging Face's Carbon-X, an AI you can chat with about DNA — but Weil's argument is that models need real-world data at scale, and that data only comes from actually making and testing compounds.

A team straight out of tech's A-list

The founding team is stacked: Weil as CEO, DJ Patil (the first U.S. chief data scientist) as COO, Sol Reisberg (ex-Terremoto Biosciences) as chief scientist, and Manohar Paluri (formerly a VP at Meta's Superintelligence Labs) as CTO. The round also drew angel investors including OpenAI's CFO Sarah Friar and chief research officer Mark Chen, Coinbase CEO Brian Armstrong, and LinkedIn co-founder Reid Hoffman. Weil himself comes from OpenAI, whose models are now landing everywhere from cloud marketplaces to coding tools.

The company is starting with about 20 people and has already bought robotic arms and AI chips, per Bloomberg's reporting. Its website says it charges per compound delivered — no compound, no charge — and it's currently working with a small number of design partners.

The take

AI had its software era. Weil's pitch is that physical science never got the lift AI gave coding and math — because progress in chemistry requires someone (or something) to physically make a compound and test it. A $215 million bet on robot chemists says the next AI revolution wears a lab coat. Keep an eye on this one.